A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 277 participants.
Also called NCT03242018
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 277 participants
- Sponsor
- Registry
-
NCT03242018
-
- Other papers using this trial's data
- Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russia, South Africa, Spain, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT03242018. Randomized; quadruple masking; primary purpose treatment. Start 2017-08-16 (actual); primary completion 2019-05-16 (actual). Results posted on 2021-06-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
- Acronym
- SOTA-CKD4
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Chronic Kidney Disease Stage 4
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Sotagliflozin
- Lead sponsor
- Lexicon Pharmaceuticals
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct03242018- Content hash
948ce1d3cc8ee1d124daa2bd6b80afb101d3db7004bf9cb3c9ebc9351a91c4ab